partnershipNeogap Therapeutics AB partners with Cellerys AGSwedish AI specialist Neogap Therapeutics AB will secect antigens for Cellerys AG, which wants to establish immune tolerance in a Phase II MS trial. more ➔
CDMODutch State to sell share capital of Intravacc BVThe State of the Netherlands, and the Dutch Ministry of Health, Welfare and Sport will sell all shares of vaccine maker Intravacc B.V. more ➔
partnershipTay Therapeutics in licensing deal with VYNE TherapeuticsTay Therapeutics Ltd announces licencing of its oral BET blocker TayB2 to VYNE Therapeutics Inc as a treatment for immuno-inflammatory and fibrotic disorders. more ➔
Medigene licences CD40L-CD28 costimulatory switch receptorGerman Medigene AG has acquired global rights to the CD40L-CD28 costimulatory switch receptor that modulates the tumour stroma in order to make T-TCR therapies more effective. more ➔
EU to decarbonise aviation sector through green fuel targetsThe European Commission has proposed to set binding sustainable aviation fuels (SAF) targets for the aviation sector to incentivise demand for and supply of SAF vs. kerosene. more ➔
Swiss Biotech Report: Sunrise, not sunset, is the feeling of the hourIn 2022, the Swiss biotech industry "continued to demonstrate its resilience, adapting well to geopolitical upheavals and remaining a key driver of innovation for global healthcare". Swiss … more ➔
Novartis in US$465m deal with 3B Pharmaceuticals GmbHTargeted radiopharmaceuticals maker 3B Pharmaceuticals snaps US$40m upfront in a global exclusive licensing agreement for its FAP-Targeting Peptide Technology. more ➔
partnershipSyngenta partners with BiotalysSyngenta has announced to leverage Biotalys’ AGROBODY technology platform to expand its biocontrol pipeline. more ➔
Phialogics AG bags pre-seed financingPhialogics AG has got a €600,000 pre-seed financing from German HTGF to validate its approach to rebalance the immune system of people with auto-immune diseases. more ➔
Forbion raises €1.35bn across two fundsEuropean life sciences venture capital company Forbion has raised two oversubscribed funds totalling €1.35 bn. more ➔
